title: Is whole-body FDG-PET valuable for health screening? Against.
authors.affiliation: Department of Nuclear Medicine, Münster University, Albert-Schweitzer-Strasse 33, 48149, Münster, Germany. m.weckesser@uni-muenster.de
authors.forename: Matthias
authors.initials: M
authors.lastname: Weckesser
authors.forename: Otmar
authors.initials: O
authors.lastname: Schober
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods* / Q000706:statistics & numerical data; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D019275:Radiopharmaceuticals; D014915:Whole-Body Counting / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
references.citation: Radiology. 2004 Feb;230(2):417-22
references.pmid: 14699176
references.citation: Ann Oncol. 2004;15 Suppl 1:I18-I26
references.pmid: 15280183
references.citation: N Engl J Med. 2000 Nov 30;343 (22):1627-33
references.pmid: 11096172
references.citation: Circulation. 2002 Jan 22;105(3):310-5
references.pmid: 11804985
references.citation: Neoplasma. 2003;50(3):217-21
references.pmid: 12937856
references.citation: Eur J Nucl Med. 1998 Jun;25(6):565-74
references.pmid: 9618570
references.citation: Anticancer Res. 2003 Sep-Oct;23 (5b):4357-61
references.pmid: 14666651
references.citation: Eur J Nucl Med. 2001 Dec;28(12 ):1766-9
references.pmid: 11734913
references.citation: Lancet. 2003 Aug 23;362(9384):593-7
references.pmid: 12944057
references.citation: Br J Cancer. 2000 Dec;83(12 ):1607-11
references.pmid: 11104553
references.citation: J Nucl Med. 2001 Jul;42(7):989-92
references.pmid: 11438616